logo
What Did Megalodon Really Eat? Probably Everything.

What Did Megalodon Really Eat? Probably Everything.

Forbes3 days ago

Lead study author Jeremy McCormack of Goethe University in Frankfurt, Germany, holds up a fossilized ... More megalodon tooth.
For decades, the giant prehistoric shark known ominously as 'The Meg" has been portrayed as a massive apex predator that hunted the only formidable opponent in the oceans at the time: whales. But new research suggests the reality was more nuanced — and a lot more interesting.
In a study published in Earth and Planetary Science Letters, scientists used advanced geochemical techniques to analyze fossilized tooth enamel and found evidence that indicate this now-extinct behemoth likely had a more varied and opportunistic diet, feeding on whatever was available in its environment to satisfy its immense appetite The key to figuring out this mystery lay in the isotopes of zinc preserved in its teeth, which serve as chemical fingerprints of what an animal ate during its life.
Researchers led by Dr. Jeremy McCormack at Goethe University in Germany analyzed 209 fossil teeth from 21 different species (both marine and terrestrial) dating back to the early Miocene period, roughly 20 to 16 million years ago. The fossils were collected from sites in what is now southern Germany, specifically a shallow seaway that once connected the ancient seas known as the Upper Marine Molasse. By focusing on a specific time and place, the team were able to compare Megalodon's diet with that of other sharks, dolphins and marine animals living at the same time.
What makes this research stand out is its use of zinc isotope ratios (specifically δ⁶⁶Zn) as a tool for estimating an animal's trophic position, or its level in the food web. While nitrogen isotopes (δ¹⁵N) have traditionally been used to track trophic levels, they can degrade over time, especially in fossils millions of years old. Zinc isotopes, on the other hand, are much more stable and are now emerging as a reliable alternative. The higher an animal is in the food chain, the lower its δ⁶⁶Zn values tend to be, because heavier zinc isotopes are preferentially retained in tissues lower down the food chain, while top predators, which eat those animals, end up with lighter zinc signatures.
In this study, Megalodon teeth consistently showed some of the lowest δ⁶⁶Zn values across the entire fossil dataset, placing them at the very top of the marine food web. The researchers also looked at the extinct Carcharodon hastalis, which is a possible ancestor of the modern great white shark, and found its δ⁶⁶Zn values were slightly higher. This suggests it fed at a slightly lower trophic level or had a different diet, supporting what many paleontologists have long suspected — that Megalodon was a top predator, likely preying on large marine mammals such as whales and dolphins. Finally, the scientists analyzed modern marine species, including sharks and dolphins, to create a baseline for comparison. They found that even today, top predators like killer whales have similarly low δ⁶⁶Zn values, further supporting the idea that zinc isotopes accurately reflect trophic level.
McCormack works at the mass spectrometer, which is used to determine the zinc isotope ratio. This ... More ratio provides information about the diet of Otodus megalodon.
Paleontologists have long suspected that Megalodon was a top predator based on its massive size, tooth morphology, and fossil evidence showing bite marks on whale bones. What this study does is go a step further by providing chemical evidence that directly links Megalodon to a high trophic level, rather than relying only on anatomical or circumstantial evidence. See, scientists face major challenges when trying to reconstruct what a creature like Megalodon actually ate. Sharks have skeletons made mostly of cartilage, which doesn't fossilize well, so researchers often rely on teeth. While bite marks on fossilized whale bones have been strong evidence of marine mammal being part of the Meg's meals, bites on other sharks leave less obvious traces, making dietary conclusions based only on physical bite evidence tricky and potentially misleading.
This new chemical analysis helps fill in those gaps.
By creating a kind of prehistoric food web, the researchers placed animals like sea bream (which eat mussels and crustaceans) at the bottom, followed by smaller sharks and extinct toothed whales the size of modern dolphins. Megalodon still sat near the top, as expected, but its zinc isotope levels weren't wildly different from those just below it in the chain, suggesting that those species may have ended up on the menu too.
While the conclusion itself (big shark ate big animals) isn't groundbreaking on its own, the method is what's novel and important. This is the first time zinc isotopes have been used in this way for extinct marine predators, and the fact that the values line up with what we see in modern apex predators opens the door to re-examining other ancient species' diets and food web roles with greater precision.
Still, it seems that ancient ecosystems are not so different from today's. Apex predators existed, food webs were complex, and adaptability was key to survival. Megalodon may have ruled the oceans, but not alone… and not without competition.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Add-On Simvastatin Shows No Benefit in Depression
Add-On Simvastatin Shows No Benefit in Depression

Medscape

time11 hours ago

  • Medscape

Add-On Simvastatin Shows No Benefit in Depression

In a trial of patients with major depressive disorder (MDD) and obesity, adding simvastatin to escitalopram treatment led to no significant reduction in depressive symptoms compared with placebo; however, the combination effectively reduced levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). METHODOLOGY: This confirmatory, double-blind, placebo-controlled trial included 160 adults (mean age, 39 years; 79% women) with MDD and comorbid obesity from nine tertiary care centres in Germany. Participants were randomly assigned to receive either simvastatin (40 mg/d; n = 81) or placebo (n = 79) as add-on to escitalopram (10 mg for the first 2 weeks, then increased to 20 mg until the end of the study) for 12 weeks. The primary outcome was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to week 12. The key secondary outcome was the change in self-reported Beck Depression Inventory II (BDI-II) scores. TAKEAWAY: Compared with the use of add-on placebo, the use of add-on simvastatin led to no significant change in MADRS scores ( P = .71) and BDI-II scores ( P = .70). = .71) and BDI-II scores ( = .70). Moreover, compared with the use of add-on placebo, the use of add-on simvastatin led to a significant reduction in levels of LDL cholesterol ( P < .001), total cholesterol ( P < .001), and CRP ( P = .003). < .001), total cholesterol ( < .001), and CRP ( = .003). Add-on simvastatin did not affect any mental health-related secondary endpoint, despite improving the cardiovascular risk profile. Four severe adverse events were reported, with no significant differences observed between the groups. IN PRACTICE: "Even though simvastatin did not exert additional antidepressive effects in our study, it had the expected and well-known effects on lipids and inflammatory activity. Given that both MDD and obesity are associated with increased cardiovascular risk and higher mortality, statins should be prescribed in this comorbid group of patients following the guidelines for statin use in primary prevention," the authors wrote. SOURCE: This study was led by Christian Otte, MD, Charité — Universitätsmedizin Berlin, Berlin, Germany. It was published online on June 04 in JAMA Psychiatry . LIMITATIONS: This study was conducted in tertiary care centres in a high-income country, with patients showing moderate symptom severity and a high response rate, which limited its generalisability. Additionally, participants with an established indication for statin treatment and those with a history of suicide attempt were not included. DISCLOSURES: This study was supported by a grant from the German Ministry of Education and Research and sponsored by Charité — Universitätsmedizin Berlin. Several authors reported receiving grants and personal fees from various sources, outside the submitted work. Details are provided in the original article.

ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium

Yahoo

time14 hours ago

  • Yahoo

ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium

Garching / Munich, Germany, June 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its recently completed Phase 3 COMPETE trial in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held from June 21 – June 24, 2025 in New Orleans, Louisiana. Details of the Oral PresentationThe data will be presented by Dr. Thomas A. Hope, MD, Chief of Nuclear Medicine at the San Francisco VA Medical Center and Vice Chair of Clinical Operations and Strategy in the Department of Radiology at UCSF in an oral presentation titled, 'Predicting the [177Lu]Lu-edotreotide uptake in tumors using pre-therapeutic Ga-68 PET/CT imaging', on Sunday, June 22 in the Neuroendocrine - Oncology Clinical Diagnosis and Therapy session from 3:30 – 4:45 pm CDT. The presentation will provide an analysis on the 177Lu-edotreotide tumor uptake and its predictability based on pre-therapeutic SSTR PET/CT imaging and other factors. Symposium DetailsThe symposium, 'Pursuing the Art and Science of RPT: COMPETE Results and the Evolution of Dosimetry,' will take place on Sunday June 22, from 6:30 pm – 7:30 pm CDT. The symposium will feature an overview of the GEP-NET treatment landscape, including findings from the Phase 3 COMPETE trial, and perspectives on dosimetry standardization today and in the future. COMPETE evaluated n.c.a 177Lu-edotreotide (also known as ITM-11) in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and ITM announced the positive Phase 3 results in March 2025. Date and Time: Sunday, June 22, from 6:30 pm – 7:30 pm CDTLocation: Ernest N. Morial Convention Center, New Orleans, LA; Room R04-R05Speakers and Topics: GEP-NET treatment landscape, COMPETE trial results, and COMPOSE trial designJonathan Strosberg, MD; Section Head, Neuroendocrine Division Program Chair, Gastrointestinal Department Oncology Research Program Moffitt Cancer Center COMPETE dosimetry sub-study and the evolution of dosimetryJohn Sunderland, PhD; Professor of Radiology Nuclear Medicine Division University of Iowa Dr. Celine Wilke Participates in Entrepreneur's PanelAs part of the SNMMI conference, Dr. Celine Wilke, ITM's Chief Medical Officer will participate in the 'Entrepreneur's Panel: Community Based Sites – Accelerating Clinical Trials and Expanding Access,' on Saturday, June 21, from 3:30 – 4:45 pm will further be present at the conference with a booth (booth number: 1001) providing information on the company's latest innovations in radiopharmaceutical therapy (RPT), its pipeline of RPT therapeutics and the company's capabilities to produce high-quality medical radioisotopes for global partners and its own pipeline. About the COMPETE TrialThe COMPETE trial evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ Attachment 20250613_ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

Yahoo

timea day ago

  • Yahoo

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said. CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at 1.04 billion euros ($1.2 billion), while BioNTech shares were down 2% by 1237 GMT. The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke. "With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said. CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. GERMAN BIOTECH CHAMPION The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress. CureVac shares were worth as much as 120 euros in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at 4.65 euros. BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda. Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said. If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476. BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac. The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer. ($1 = 0.8624 euros) (Additional reporting by Christian Kraemer; Editing by Friederike Heine, Jan Harvey and Emelia Sithole-Matarise)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store